FindTrial
Sign In

Comparison of two contraceptive pills containing ethinylestradiol 20 µg/drospirenone 3 mg and ethinylestradiol 35ug/cyproterone acetate 2mg in the treatment of polycystic ovary syndrome: a multicenter randomized controlled trial

Comparison of two contraceptive pills containing ethinylestradiol 20 µg/drospirenone 3 mg and ethinylestradiol 35ug/cyproterone acetate 2mg in the treatment of polycystic ovary syndrome: a multicenter randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018603
Enrollment
Unknown
Registered
2018-09-30
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

A:YAZ
B:Diane 35

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients are diagnosed PCOS according to the Rotterdam's criteria; 2. aged between 18 and 40 years old; 3. no pregnance plan currently.

Exclusion criteria

Exclusion criteria: 1. Patients who got the contraindications of taking Drospirenone and Ethinylestradiol Tablets (II) or Diane 35; 2. patients who have been treated with hormone or metabolic drugs within 3 months.

Design outcomes

Primary

MeasureTime frame
Hyperandrogenism and biochemical indicators;Menstrual cycle control and bleeding patterns;carbohydrate metabolism;—

Secondary

MeasureTime frame
body mass index;waist circumference;Waist-to-hip ratio;blood pressure;lipid metabolism;the ratio of LH/FSH;—

Countries

China

Contacts

Public ContactHuang Wei
weihuang64@163.com+86 18180609196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026